

This is a pre-print of an article published in *Central European Journal of Medicine*. The final authenticated version is available online at: <https://doi.org/10.2478/s11536-011-0038-9>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **HLA-C genotype and TCR v β expression analysis in Mexican patients with Psoriasis**

2
3 Leticia Santos^{1*}, Ma. Fabiola León-Galvan¹, Cornelia Fuentes-Ahumada², Erika Nahomy
4 Marino-Marmolejo¹, Verónica del Carmen Martínez-Jiménez¹, Antonio De León-Rodríguez¹,
5 Ana Paulina Barba de la Rosa¹, Bertha Torres-Alvarez², Benjamín Moncada-González²

6
7 ¹Division of Molecular Biology, Institute for Scientific and Technological Research of San Luis
8 Potosi (IPICYT), San Luis Potosi, Mexico

9 ²Department of Dermatology, Hospital Central Dr. Ignacio Morones Prieto, Universidad
10 Autonoma de San Luis Potosí (UASLP), San Luis Potosi, Mexico

11
12 *Correspondence: Dr. Leticia Santos, Division of Molecular Biology, IPICYT, Camino a la
13 Presa San Jose 2055, Col. Lomas 4a. Seccion, CP 78216, San Luis Potosí, SLP, Mexico, tel.+52
14 44 48 34 20 00; fax +52 44 48 34 20 10; E-mail: lsantos@ipicyt.edu.mx

15
16 Short title: HLA and TCR v β analysis in psoriatic Mexican patients

17
18 Abbreviations: TCR v β , T-cell receptor beta-chain variable; HLA, Human Leukocyte Antigen;
19 RT-PCR, Reverse Transcriptase-Polymerase Chain Reaction; SSP-PCR, Sequence-Specific
20 Primer-Polymerase Chain Reaction.

1
2
3 **Abstract**
4
5
6
7

8 Genetic background and T-cell expansion have been associated as the most important factors for
9
10 psoriasis susceptibility in the Caucasian population. This study was performed to identify the T-
11
12 cell receptor V β repertoire and HLA-Cw genotype in two Mexican groups with severe chronic
13
14 plaque-type psoriasis. HLA-C typing was performed to detect the allele pattern associated with
15
16 the disease by sequence-specific primer-polymerase chain reaction. In parallel, RT-PCR and
17
18 Western blot were used for the identification of the TCR V β repertoire. We found a wide variety
19
20 of HLA-C alleles displayed with a preference to HLA-Cw *07 as the most representative allele
21
22 in the group of patients. TCR V β -2 and V β -7 clone-type frequencies were statistically significant
23
24 (p of 0.0280) when compared to other TCR V β expressed in the two groups. We found notable
25
26 differences both in the HLA-C genotype and TCR V β repertoire in the groups of patients studied.
27
28 Since Mexican individuals are genetically different from the Caucasian population, we suggest
29
30 that due to these differences the susceptibility to disease and activation of T-cells for a proper
31
32 immune response may be affected.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Introduction

2
3
4
5
6
7
8 Psoriasis is a common, chronic, inflammatory skin disease, with a prevalence of over 1% in most
9
10 populations; however among Caucasians it has a prevalence of 2-4% (Nevitt *et al.*, 1996).
11
12 Raychaudhuri *et al.* (2001) reported the prevalence of psoriasis around the world including
13
14 North, Central and South America. In Mexico, psoriasis is seen with a frequency similar to
15
16 reports worldwide; nevertheless the population is characterized by a mixed ethnicity of native
17
18 Mexican indigenous and white people denominated as Mestizo. In addition, we have noticed an
19
20 important prevalence of this disease in a purely indigenous population in a subtropical area of the
21
22 state of San Luis Potosi in Mexico. To date, only a few studies have been conducted in the search
23
24 for the genetic background of non-Caucasian ethnic groups in association with psoriasis risk
25
26 (Chang *et al.*, 2005; Holm *et al.*, 2005; Yan *et al.*, 2008). *HLA-C*, *CDSN*, *CCHCR1*, *SEEK*, and
27
28 *PSORSIC3* alleles have been described by genetic linkage analyses to elucidate the association
29
30 between the major histocompatibility complex (MHC) class I region and the susceptibility locus
31
32 (*PSORS1*). Other inflammatory diseases are associated with polymorphisms at MHC class I
33
34 genes, for example, ankylosing spondylitis with the HLA-B27 allele (Higgins *et al.*, 1992) and
35
36 subacute thyroiditis with the HLA-B35 allele (Kramer *et al.*, 2004). However, psoriasis is the
37
38 only inflammatory disease that strongly associates with HLA-Cw*0602 (Nair *et al.*, 2006).
39
40
41
42
43
44

45
46 The pathogenesis of psoriasis still remains elusive; the type 1 T-cells have been involved
47
48 through the secretion of their cytokines, which contributes to the epidermal hyperproliferation. It
49
50 has been proposed that psoriasis is a disease of activated innate immunity to explain the relation
51
52 between the environmental factors and the exacerbation of the psoriasis (Nickoloff *et al.*, 2004),
53
54 but in the treatment of severe psoriasis, the good response to drugs blocking T-cell activation
55
56
57
58
59
60

1 supports the idea that T-cell activation plays a key role in the inflammatory reaction. The antigen
2 could be either internal (autoimmune disease) or external. In addition it is not known whether in
3 different clinical types of the disease the responsible antigen is the same each time, or different
4 ones. Superantigens, unlike conventional antigens, activate T-cells expressing certain T-cell
5 receptors, which possess a region highly variable known as the variable β region (TCR V β). The
6 importance of this region and its role in autoimmune diseases has been determined by Bour *et al.*
7 (1999), although several authors have found differences in the expression of the TCR V β usage
8 for the presentation of antigens to the MHC class II on antigen presenting cells (Chang *et al.*,
9 1994; Vollmer *et al.*, 2001; Hwang *et al.*, 2003). Preferential usage of certain T-cell receptors by
10 the lymphocytic infiltrate in psoriasis might indicate the involvement of one or several antigens
11 in the pathogenesis of psoriasis. Thus a significant change in the pattern of V β expression is
12 likely to occur in T-cells responding to such stimuli.

13 We present our findings in the analysis of the human leukocyte antigen (HLA) alleles Cw
14 type and the frequency of the TCR V β usage in a group of native indigenous and Mestizo
15 Mexican patients in their risk for psoriasis.

17 **Results**

19 **Haplotype and allelic frequencies of HLA-C loci**

21 The frequencies for each HLA-C allele identified by PCR-SSP are shown in Table 1. The alleles
22 of these loci are not represented in all the tested subjects and could be found only rarely in some
23 patients of the two groups studied. It can be observed that HLA-Cw*07*07 (30%) and HLA-

1
2
3 1 Cw*03*07 (20%) are the most frequent alleles in the psoriatic patients from group 1, but this
4
5 2 was different in group 2: HLA-Cw*01*08* (10%), -Cw*03*12, -Cw*04*16, -Cw*04*12, -
6
7
8 3 Cw*05*07, -Cw*06*08, -Cw*07*08.
9
10
11 4

12 5 **TCR V β expression analysis**

13
14
15 6
16
17 7 The hypervariable region of the TCR V β gene family was examined as reported by several
18
19 8 authors (Ahangari *et al.*, 1997; Bour *et al.*, 1999; Fernandes *et al.*, 2005). PBMCs were used for
20
21 9 the isolation of total mRNA. To obtain an overall scheme of the V β transcript expression, we
22
23 10 included a set of 24 oligonucleotides for the RT-PCR experiments reported by Fernandes *et al.*
24
25 11 (2005). Results are shown in Figure 1. A subset of regions within group 1 is observed, the V β 2,
26
27 12 V β 7 and V β 23 subfamilies were predominantly expressed. In contrast, the expression profile of
28
29 13 group 2 shows a wider usage of V β s, such as V β 1, V β 2, V β 6, V β 7, V β 13S2, V β 15, V β 16, V β 20
30
31 14 and V β 23.
32
33
34
35

36 15 To confirm these results, the expression profile was analyzed at protein level with a
37
38 16 selected panel of monoclonal antibodies against specific segments of the TCR V β receptors
39
40 17 described in *Materials and Methods*. Western blot experiments were performed with crude
41
42 18 extract of PBMCs. Results illustrate that all samples of group 1 displayed positive bands for all
43
44 19 TCRs analyzed as shown in Figure 2. Only 50% of the samples from group 2 displayed a similar
45
46 20 pattern.
47
48
49

50 21 A comparison of TCR V β s expression between RT-PCR and Western blot analysis was
51
52 22 done using Fisher's exact test to prove the association between the methods and the groups
53
54
55
56
57
58
59
60

1 studied. Statistical analyses showed TCR V β -2 and V β -7 were predominantly expressed in both
2 groups with a p of 0.0280.

4 **Discussion**

5
6 Susceptibility to psoriasis has been investigated through the study of the MHC I genes
7 supporting the allele Cw*0602 in pure Caucasian populations (Holm *et al.*, 2005; Nair *et al.*,
8 2006). Unlike those reports, we have shown 14 distinct risk alleles in the Mexican patients
9 analyzed (Table 1). From the two groups studied, we identified a wider variety of alleles among
10 Mestizo patients that have a Caucasian background (group 2), but the allele *06 is rarely present.
11 A study performed by Fan *et al.* (Fan *et al.*, 2008), suggest that ethnic population might transmit
12 distinctive susceptibility alleles because of the genetic heterogeneity of *PSORS1* locus. To date
13 none of the alleles shown in Table 1 have been reported in association with psoriasis, even in the
14 Chinese (Fan *et al.*, 2007; Fan *et al.*, 2008) or the Sardinian (Lio *et al.*, 2003; Orru *et al.*, 2005;
15 Scola *et al.*, 2008) populations. We suggest that for the group of patients included in this study,
16 Cw*07 is the most prevalent allele in association with the disease.

17 The TCR repertoire was studied in PBMC by RT-PCR and Western blot. Transcript
18 analysis shows a preferential usage of the V β -2, -7 and -23 in group 1 (gray bars) and a larger
19 usage in group 2 (black bars): V β -1, -2, -6, -7, -13S2, -15, -20 and -23 (Figure 1). Frequency
20 analysis bearing TCR V β in PBMCs with the monoclonal antibodies here acquired, produced
21 significant differences between the two groups. All samples of group 1 expressed every TCR V β
22 clone type, while in group 2, only five patients produced the same results. Statistical analysis
23 showed a $p < 0.05$ using the χ^2 test (Figure 2). Statistical analysis including transcript and protein

1 results suggests two major restricted T-cell expansions, TCR V β -2 and TCR V β -7. Evidence of
2 the TCR V β -2 expression bias has been already reported for T-cells that are destined to migrate
3 to the skin (Kay *et al.*, 1995; Yoshioka *et al.*, 1999; Menssen *et al.*, 2000). TCR V β -7 expression
4 has been studied in psoriasis as well as in several normal tissues and other diseases (Hodges *et*
5 *al.*, 1998; Nickoloff *et al.*, 2004; Dokouhaki *et al.*, 2006). Since all samples from group 1 were
6 positive using Western blot in PBMC, we decided to examine random skin biopsies (n=6) by
7 immunohistochemistry. We included apparently normal skin biopsies and lesions from the same
8 patients. Infiltrating T-cells were detected in the non-lesional skin biopsies while in lesional skin,
9 paucity of T-cells was observed (data not shown). This inconsistency has been reported by other
10 authors (Komatsu *et al.*, 1996; Carlen *et al.*, 2007), and could be explained by the event dubbed
11 as K \ddot{o} bner response (Hwang *et al.*, 2003).

12 Previous studies have reported selectivity of the clones displaying different TCR V β of
13 infiltrated T-cells in psoriatic lesions: TCR V β -13 and -15 (Chang *et al.*, 1994); TCR V β -5.1, -
14 11, -12, -13.1 and -16 (Ahangari *et al.*, 1997); TCR V β -3 and -13.1 (Bour *et al.*, 1999) and more
15 recently TCR V β -3, -13S2 and -21 (Diluvio *et al.*, 2006). This evidence is bound to studies of
16 patient specimens with streptococcal infections. In correlation to these data, Kansal *et al.* (2003)
17 reported a T-cell expansion expressing TCR V β -4, -7 and -8 triggered by a superantigen-
18 induced by a specific streptococcal protease. The mechanism has been extensively discussed for
19 psoriasis onset; however, the superantigen theory has not been entirely proved. We may
20 speculate that similar T-cell events occur for the selection of the TCR V β in our study although
21 the study for the identification of the antigen(s) involved by means of mass spectrometry would
22 provide interesting data.

1 In the present report we have shown a major expansion of two TCR V β s and a
2 preferential HLA-C haplotype in the group of patients studied. These preliminary findings could
3 lead to future tailor-made strategic treatments for the Mexican population.

4 5 **Materials and methods**

6 7 **Patients**

8
9 This study included ten native indigenous patients of the subtropical region of San Luis Potosi
10 State (group 1) and ten Mestizo patients living in the capital city of San Luis Potosi (group 2).

11 The patients from ages between 24 to 74 years old presented active chronic plaque-type psoriasis
12 (CPP). The diagnosis was based on clinical and histopathological data of the skin lesions. All
13 patients signed consent letters under the *Declaration of Helsinki* and the use of all samples and
14 the experimental procedure for this study were reviewed and approved by the Ethics and
15 Research Committee of the Central Hospital Dr. Ignacio Morones Prieto, Universidad Autonoma
16 de San Luis Potosi in San Luis Potosi city, Mexico.

17 18 **Samples**

19
20 A 2-mm biopsy of the psoriatic skin lesion and another from a distant apparently normal zone
21 were obtained from each person. All specimens were immediately frozen in liquid nitrogen and
22 then transferred to -80°C until use. Peripheral blood was obtained from each patient and the
23 heparinized peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation by the

1
2
3 1 Ficoll-Hypaque method (Sigma). Cells were washed twice with sterile PBS, snap frozen and
4
5 2 stored at -80°C until use.
6
7
8 3

10 4 **HLA genotyping and data analysis**

11
12 5
13 6 Genomic DNA was extracted from PBMCs using the UltraClean™ Blood DNA Isolation Kit
14
15 7 (Non-Spin) (MO BIO Laboratories Inc.). The HLA-Cw genotype was analyzed by sequence-
16
17 8 specific primer-polymerase chain reaction (SSP-PCR) in the Transplantation Laboratory / HLA
18
19 9 Laboratory of the Haartman Institute at the University of Helsinki, Finland. Genotype
20
21 10 frequencies of different haplotypes were obtained by direct counting and we reported frequencies
22
23 11 of each allele.
24
25
26
27
28
29
30
31
32
33

32 13 **TCR V β expression analysis by RT-PCR**

33
34 14
35
36 15 The PBMCs were homogenized in Trizol (Invitrogen) and RNA isolation was done according to
37
38 16 the manufacturer's instructions. The final RNA pellet was resuspended in 20 μ L of RNase-free
39
40 17 diethyl-pyrocabonate-treated water. The isolated RNA was reverse transcribed using oligo-dT
41
42 18 primer and SuperScript II RNase H Reverse Transcriptase (Invitrogen). For amplification of the
43
44 19 cDNAs we have used the set of primers described by Fernandes *et al.* (Fernandes *et al.*, 2005).
45
46 20 The RT-PCR products were run in 2% agarose gel and stained with ethidium bromide.
47
48
49
50
51
52

53 22 **Antibodies**

54
55 23
56
57
58
59
60

1 The following murine anti-human monoclonal antibodies were purchased from Biodesign
2 International: V β -2 (clone MPB2D5) which recognizes all alleles of the single member of V
3 beta-2 family, V β -7 (clone ZOE) recognizes V-beta-7.1, V β -11 (clone C21) recognizes the two
4 known sequences PL3.12 and PH15, V β -13.1 (Immu222) recognizes the V beta-13.1 member,
5 V β -17 (clone E17.5F3), V β -20 (clone ELL 1.4) and V β -22 (Immu546) recognizes at least the
6 IGRb03 sequence.

8 **TCR V β expression analysis by Western blot**

9
10 The PBMCs cells and skin biopsies were homogenized by sonication and protein quantitation
11 was performed by the Lowry method (Sigma). BSA was used for the standard curve and the
12 absorption was measured at 590 nm. 50 μ L of total protein extract at 5 μ g/ μ L were mixed with
13 4x loading buffer and heated at 95°C for 5 minutes before loading onto a 12.5% SDS
14 polyacrylamide gel. Electrophoresis was subjected at a constant current of 2mA/cm at room
15 temperature. Separated proteins were transferred onto nitrocellulose membranes (Amersham)
16 using a Bio-Rad Semi-Dry Electrophoretic Transfer Cell following the manufacturer's
17 instructions. The membranes were incubated with a panel of monoclonal antibodies above
18 described against TCR V β diluted 1:5,000 in blocking solution for 1-2 hours. Excess of antibody
19 was removed by several washing steps prior to the incubation with the secondary antibody anti-
20 mouse IgG alkaline phosphatase-conjugated from Sigma diluted 1:10,000. Lastly, the
21 membranes were washed and developed with 10 mL of developing solution containing 66 μ L
22 NTB (Sigma) and 33 μ L BCIP (Sigma) until color appeared. The reaction was stopped with 10
23 mL stop solution.

1
2
3 1
4
5
6 2 **Statistical analysis**
7
8 3
9
10 4 The statistical analysis between the frequency of the six different TCR V β expressions produced
11
12 5 by Western blot in patients from Group 1 and 2 was done using an X^2 test. Fisher's exact test was
13
14 6 used to associate the expression of the TCR V β s present in the two groups studied and the two
15
16 7 methods performed by a 2x2 contingency table. Analysis was executed using the InStat software
17
18 8 program v.3.0 (GraphPad 5.0 Software, San Diego, CA). Values of $p < 0.05$ were considered as
19
20 9 significant.
21
22
23
24 10
25
26
27 11 **Conflict of interest**
28
29 12
30
31 13 The authors state no conflict of interest.
32
33
34 14
35
36 15 **Acknowledgements**
37
38 16
39
40 17 We are grateful to Edgar Ortíz Brizuela from the Medical undergraduate program of the
41
42 18 University of San Luis Potosi, Mexico, for his participation in this project during the 10th *Verano*
43
44 19 *de la Ciencia* for his performance in the immunohistochemical studies.
45
46
47 20
48
49 21
50
51 22
52
53 23
54
55
56
57
58
59
60

1
2
3 **1 References**
4

- 5
6 2
7
8 3 Ahangari G, Halapi E, Tehrani MJ, Fransson J, Hammar H, Wigzell H (1997). RT-PCR
9
10 4 topography of chronic psoriasis skin based on analysis of T-cell receptor B variable
11
12 5 region gene usage. *Scand J Immunol* 45:534-540.
13
14
15 6 Bour H, Puisieux I, Even J, Kourilsky P, Favrot M, Musette P, Nicolas JF (1999). T-cell
16
17 7 repertoire analysis in chronic plaque psoriasis suggests an antigen-specific immune
18
19 8 response. *Hum Immunol* 60:665-676.
20
21
22 9 Carlen L, Sakuraba K, Stahle M, Sanchez F (2007). HLA-C expression pattern is spatially
23
24 10 different between psoriasis and eczema skin lesions. *J Invest Dermatol* 127:342-348.
25
26
27 11 Chang JC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek
28
29 12 MA, Wilkinson DI, Carlo DJ, *et al.* (1994). CD8+ T cells in psoriatic lesions
30
31 13 preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. *Proc Natl Acad Sci*
32
33 14 *U S A* 91:9282-9286.
34
35
36 15 Chang YT, Liu HN, Shiao YM, Lin MW, Lee DD, Liu MT, Wang WJ, Wu S, Lai CY, Tsai SF
37
38 16 (2005). A study of PSORS1C1 gene polymorphisms in Chinese patients with psoriasis.
39
40 17 *Br J Dermatol* 153:90-96.
41
42
43 18 Diluvio L, Vollmer S, Besgen P, Ellwart JW, Chimenti S, Prinz JC (2006). Identical TCR beta-
44
45 19 chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis
46
47 20 vulgaris. *J Immunol* 176:7104-7111.
48
49
50 21 Dokouhaki P, Moghadam R, Akbariasbagh F, Zarnani A, Novin MG, Razavi A, Jeddi-Tehrani M
51
52 22 (2006). Expression profile and clonality of T-cell receptor beta variable genes in normal
53
54 23 human endometrium. *Am J Reprod Immunol* 55:349-359.
55
56
57
58
59
60

- 1
2
3 1 Fan X, Yang S, Huang W, Wang ZM, Sun LD, Liang YH, Gao M, Ren YQ, Zhang KY, Du WH,
4
5 2 Shen YJ, Liu JJ, Zhang XJ (2008). Fine mapping of the psoriasis susceptibility locus
6
7 3 PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. *PLoS*
8
9 4 *Genet* 4:e1000038.
- 10
11
12 5 Fan X, Yang S, Sun LD, Liang YH, Gao M, Zhang KY, Huang W, Zhang X (2007). Comparison
13
14 6 of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han
15
16 7 Chinese population. *Acta Derm Venereol* 87:335-340.
- 17
18
19 8 Fernandes S, Chavan S, Chitnis V, Kohn N, Pahwa S (2005). Simplified fluorescent multiplex
20
21 9 PCR method for evaluation of the T-cell receptor V beta-chain repertoire. *Clin Diagn Lab*
22
23 10 *Immunol* 12:477-483.
- 24
25
26 11 Higgins CM, Lund T, Shipley ME, Ebringer A, Sadowska-Wroblewska M, Craig RK (1992).
27
28 12 Ankylosing spondylitis and HLA-B27: restriction fragment length polymorphism and
29
30 13 sequencing of an HLA-B27 allele from a patient with ankylosing spondylitis. *Ann Rheum*
31
32 14 *Dis* 51:855-862.
- 33
34
35 15 Hodges E, Dasmahapatra J, Smith JL, Quin CT, Lanham S, Krishna MT, Holgate ST, Frew AJ
36
37 16 (1998). T cell receptor (TCR) Vbeta gene usage in bronchoalveolar lavage and peripheral
38
39 17 blood T cells from asthmatic and normal subjects. *Clin Exp Immunol* 112:363-374.
- 40
41
42 18 Holm SJ, Sanchez F, Carlen LM, Mallbris L, Stahle M, O'Brien KP (2005). HLA-Cw*0602
43
44 19 associates more strongly to psoriasis in the Swedish population than variants of the novel
45
46 20 6p21.3 gene PSORS1C3. *Acta Derm Venereol* 85:2-8.
- 47
48
49 21 Hwang HY, Bahk YY, Kim TG, Kim TY (2003). Identification of a commonly used CDR3
50
51 22 region of infiltrating T cells expressing Vbeta13 and Vbeta15 derived from psoriasis
52
53 23 patients. *J Invest Dermatol* 120:359-364.
- 54
55
56
57
58
59
60

- 1
2
3 1 Kansal RG, Nizet V, Jeng A, Chuang WJ, Kotb M (2003). Selective modulation of superantigen-
4 induced responses by streptococcal cysteine protease. *J Infect Dis* 187:398-407.
5
6 2
7
8 3 Kay RA, Hutchings CJ, Ollier WE (1995). A subset of Sjogren's syndrome associates with the
9
10 4 TCRBV13S2 locus but not the TCRBV2S1 locus. *Hum Immunol* 42:328-330.
11
12 5 Komatsu T, Moriya N, Shiohara T (1996). T cell receptor (TCR) repertoire and function of
13 6 human epidermal T cells: restricted TCR V alpha-V beta genes are utilized by T cells
14 7 residing in the lesional epidermis in fixed drug eruption. *Clin Exp Immunol* 104:343-350.
15
16 8 Kramer AB, Roozendaal C, Dullaart RP (2004). Familial occurrence of subacute thyroiditis
17 9 associated with human leukocyte antigen-B35. *Thyroid* 14:544-547.
18
19 10 Lio D, Pes GM, Carru C, Listi F, Ferlazzo V, Candore G, Colonna-Romano G, Ferrucci L,
20 11 Deiana L, Baggio G, Franceschi C, Caruso C (2003). Association between the HLA-DR
21 12 alleles and longevity: a study in Sardinian population. *Exp Gerontol* 38:313-317.
22
23 13 Menssen A, Vollmer S, Trommler P, Sander C, Prinz JC (2000). Analysis of the TCRBV
24 14 repertoire of T cells in normal, human skin: evidence for a restricted diversity. *J Invest*
25 15 *Dermatol* 115:66-73.
26
27 16 Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, Weichenthal M, Abecasis
28 17 GR, Lim HW, Christophers E, Voorhees JJ, Elder JT (2006). Sequence and haplotype
29 18 analysis supports HLA-C as the psoriasis susceptibility 1 gene. *Am J Hum Genet* 78:827-
30 19 851.
31
32 20 Nevitt GJ, Hutchinson PE (1996). Psoriasis in the community: prevalence, severity and patients'
33 21 beliefs and attitudes towards the disease. *Br J Dermatol* 135:533-537.
34
35 22 Nickoloff BJ, Nestle FO (2004). Recent insights into the immunopathogenesis of psoriasis
36 23 provide new therapeutic opportunities. *J Clin Invest* 113:1664-1675.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 Orru S, Giuressi E, Carcassi C, Casula M, Contu L (2005). Mapping of the major psoriasis-
4
5 2 susceptibility locus (PSORS1) in a 70-Kb interval around the corneodesmosin gene
6
7 3 (CDSN). *Am J Hum Genet* 76:164-171.
8
9
10 4 Raychaudhuri SP, Farber EM (2001). The prevalence of psoriasis in the world. *J Eur Acad*
11
12 5 *Dermatol Venereol* 15:16-17.
13
14
15 6 Scola L, Lio D, Candore G, Forte GI, Crivello A, Colonna-Romano G, Pes MG, Carru C,
16
17 7 Ferrucci L, Deiana L, Baggio G, Franceschi C, Caruso C (2008). Analysis of HLA-
18
19 8 DRB1, DQA1, DQB1 haplotypes in Sardinian centenarians. *Exp Gerontol* 43:114-118.
20
21
22 9 Vollmer S, Menssen A, Prinz JC (2001). Dominant lesional T cell receptor rearrangements
23
24 10 persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable
25
26 11 antigen-specific pathogenic T cell response in psoriasis vulgaris. *J Invest Dermatol*
27
28 12 117:1296-1301.
29
30
31 13 Yan LN, Li SY, Dong Z, Dong L, Xie JH, An SP, Yuan YH (2008). Sequence-based typing
32
33 14 reveals the novel HLA-DRB1*1467 allele in a Chinese individual. *Tissue Antigens*
34
35 15 72:409-410.
36
37
38 16 Yoshioka T, Matsutani T, Iwagami S, Toyosaki-Maeda T, Yutsudo T, Tsuruta Y, Suzuki H,
39
40 17 Uemura S, Takeuchi T, Koike M, Suzuki R (1999). Polyclonal expansion of TCRBV2-
41
42 18 and TCRBV6-bearing T cells in patients with Kawasaki disease. *Immunology* 96:465-
43
44 19 472.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 Tables**4
5
6 **2**7
8 **Table 1. HLA-C allele frequency of the two psoriatic groups by SSP-PCR**

HLA-Cw*	Group 1 ¹ (%)	Group 2 ¹ (%)
	(n=10)	(n=10)
*01*03	1 (0.1)	0
*01*08	0	1 (0.1)
*03*04	1 (0.1)	1 (0.1)
*03*07	2 (0.2)	0
*03*12	0	1 (0.1)
*04*07	1 (0.1)	1 (0.1)
*04*16	0	1 (0.1)
*04*12	0	1 (0.1)
*05*07	0	1 (0.1)
*06*08	0	1 (0.1)
*07*07	3 (0.3)	0
*07*08	0	1 (0.1)
*07*15	1 (0.1)	1 (0.1)
*08*08	1 (0.1)	0

¹Group 1 corresponds to indigenous patients; Group 2, Mestizo patients.


9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 **3**52
53
54 **4**55
56
57 **5**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1 **Figures**

2 Figure 1.

a




b




3

4

1 Figure 2.

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

b



1
2
3 1 **Figure legends**
4

5 2
6
7
8 3 **Figure 1.** (a) Transcript analysis of the 24 TCR V β chains in peripheral blood reported as
9
10 4 frequency from Mexican native indigenous (group 1, gray bars) and Mestizo patients (group 2,
11
12 5 black bars) with CPP lesions. (b) RT-PCR products were analyzed on 1% agarose gels. We show
13
14 6 the amplification of TCR V β -2 and -7 and the β -actin as internal control.
15
16
17 7

18
19
20 8 **Figure 2.** (a) Detection of TCR V β s (2, 7, 11, 13S1, 17 and 22) at protein level in peripheral
21
22 9 blood derived from Mexican native indigenous (group 1, gray bars) and Mestizo patients (group
23
24 10 2, black bars). (b) TCR V β -2 and -7 blots detected with monoclonal antibodies as described in
25
26
27 11 *Materials and Methods.*
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60